Legal & General Group Plc Has $148.04 Million Stake in Illumina, Inc. $ILMN

Key Points

• Legal & General Group Plc cut its Illumina stake by 9.3% in the fourth quarter, but still held 1.13 million shares worth about $148.0 million.
• Illumina saw notable insider selling, including a large sale by Director Keith A. Meister, and insiders sold 330,160 shares worth roughly $48.0 million over the last quarter.
• The company’s recent news flow was mixed to positive: Illumina reported better-than-expected quarterly earnings and revenue and launched new oncology sequencing tools, while analysts currently rate the stock around Hold on average.

Legal & General Group Plc decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 1,128,669 shares of the life sciences company's stock after selling 116,019 shares during the period. Legal & General Group Plc owned 0.74% of Illumina worth $148,036,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new position in shares of Illumina during the 4th quarter valued at about $25,000. Board of the Pension Protection Fund acquired a new position in shares of Illumina during the 4th quarter valued at about $26,000. Creative Capital Management Investments LLC increased its holdings in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in shares of Illumina during the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Illumina during the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Insider Buying and Selling at Illumina

In related news, SVP Christensen Jakob Wedel sold 700 shares of the company's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 225,067 shares of Illumina stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the sale, the director directly owned 3,604,441 shares in the company, valued at $524,626,387.55. The trade was a 5.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 330,160 shares of company stock valued at $48,028,308. Corporate insiders own 2.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ILMN shares. Wall Street Zen lowered Illumina from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 9th. Piper Sandler lowered their price objective on Illumina from $195.00 to $170.00 and set an "overweight" rating on the stock in a report on Monday, February 9th. Daiwa Securities Group raised Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 price objective on the stock in a report on Thursday, May 14th. Canaccord Genuity Group lowered their price objective on Illumina from $150.00 to $140.00 and set a "hold" rating on the stock in a report on Friday, May 1st. Finally, JPMorgan Chase & Co. increased their price objective on Illumina from $120.00 to $125.00 and gave the company a "neutral" rating in a report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $137.75.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina and SPT Labtech launched fireflyGO, a new automation platform designed to make targeted oncology research faster, simpler, and more scalable. The product is integrated with Illumina’s MiSeq i100 Series and could help broaden adoption of its sequencing workflow. Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
• Positive Sentiment: Illumina also introduced a distributed whole-genome sequencing solution for MRD research, expanding its oncology portfolio and making it easier for more labs to adopt molecular residual disease testing in clinical research. That supports the company’s long-term growth narrative in precision oncology. Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
• Neutral Sentiment: A separate marketwide report noted that the broader stock market reached fresh highs on upbeat macro news. While this may be helping overall sentiment, it is not specific to Illumina’s business. Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings
• Neutral Sentiment: One article flagged Illumina as a strong momentum stock, which may reinforce positive trader sentiment, but it did not include new fundamental information. Here's Why Illumina (ILMN) is a Strong Momentum Stock

Illumina Price Performance

NASDAQ:ILMN opened at $158.70 on Friday. The stock has a market cap of $24.01 billion, a P/E ratio of 28.85, a PEG ratio of 2.49 and a beta of 1.42. Illumina, Inc. has a one year low of $78.79 and a one year high of $158.79. The company has a fifty day moving average price of $132.92 and a 200 day moving average price of $131.80. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts anticipate that Illumina, Inc. will post 5.2 earnings per share for the current year.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.